logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developingā€¦ read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.91

Price

+2.49%

$0.02

$0.89

Previous Close

$0.86

Open

Premium

52w Discount
Market Cap

$42.495m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$59.070k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$36.602m

+2.7%

1y CAGR

+3.3%

3y CAGR

-32.9%

5y CAGR
EPS

-$0.93

+9.7%

1y CAGR

+12.8%

3y CAGR

-19.6%

5y CAGR
Book Value

$15.960m

$40.476m

Assets

$24.516m

Liabilities

$18.537m

Debt
Debt to Assets

45.8%

-0.6x

Debt to EBITDA
Free Cash Flow

-$34.367m

+2.0%

1y CAGR

-11.0%

3y CAGR

-34.7%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.